No Stock Yet
Ruike Biology-B (02179): he Yanqun is appointed as joint company secretary and legal process agent
Zitong Financial App News, Ruike Bio-B (02179) announced that the company has appointed Fangyuan Enterprise Services Group (Hong Kong) Co., Ltd. (Fangyuan) to provide company secretarial support to the company. Fang Yuan has nominated Liu Junyu as joint company secretary and agent of process in Hong Kong (agent of process) (receiving process on behalf of the company in Hong Kong under part 16 of the companies Ordinance, Cap. 622) and on behalf of the company in Hong Kong under Rule 19A.13 of the rules governing the listing of Securities on the Stock Exchange of Hong Kong Limited; and
Ruike Biology-B (02179) elected Liu Ping as the employee representative supervisor
Zitong Financial App News, Ruike Bio-B (02179) announced that due to job changes, Gu Zhongcai and Wang Hongyang have submitted their resignation as supervisors of the company's first board of supervisors on June 30th, 2022. Wang Hongyang's resignation will take effect from June 30th, 2022. Gu Zhongcai's resignation will take effect after the revision of the company's articles of association has been completed. On June 30, 2022, Liu Ping was elected as the employee representative supervisor at the workers' Congress of the company, effective from now on.
Ruike Bio-B (02179) plans to participate in H-share full circulation plan
Zitong Financial App News, Ruike Bio-B (02179) announced that the board of directors has approved on June 30th, 2022, to convert about 222 million domestic shares into H shares of the company. After the completion of the full circulation of H shares, the total number of H shares of the company will be changed to about 316 million shares, accounting for 65.46% of the total share capital of the company. In the intention of this H-share full circulation application, all the 222 million shares proposed to apply for this H-share full circulation are domestic shares, and no unlisted foreign capital shares participate in this H-share full circulation application.
Recbio Technology Cleared to Start COVID Vaccine's Clinical Study in the Philippines
03:47 AM EDT, 06/27/2022 (MT Newswires) -- Jiangsu Recbio Technology (HKG:2179) obtained regulatory approval to begin the clinical trial of R520A in the Philippines. R520A is an mRNA COVID-19 vaccine
Ruike Bio-B (02179.HK): COVID-19 mRNA Vaccine of Omicron Mutant is clinically licensed in the Philippines
02179.HK announced that the Group has recently received clinical trial approval ("Clinical trial approval") from the Philippine State Food and Drug Administration for its novel coronavirus mRNA vaccine R520A ("R520A"). R520A is a mRNA vaccine developed by Wuhan Ruikeji Biotechnology Co., Ltd., a subsidiary of the company, against novel coronavirus Omicron mutant strain. By using the freeze drying technology developed by ourselves, R520A can effectively maintain the physical and chemical properties and biological activity of mRNA-LNP and grow at 2-8 ℃.
Ruike Biology-B (02179) appoints Wang Feizhou as Supervisor
Zitong Financial App News, Ruike Bio-B (02179) issued an announcement that Wang Feizhou was appointed as the supervisor at the annual general meeting. Xu Yaming has resigned as supervisor with effect from June 17, 2022.
HPV vaccine hundreds of billions of stock market! Zhongtai Securities: where are the opportunities for domestic enterprises?
Zhitong Financial APP learned that Sino-Thai Securities issued a research report saying that the domestic HPV vaccine vaccination rate is low, the stock market space is broad, and it will still be a supply-driven market in the short term. The bank is optimistic about companies with leading progress and strong sales ability, such as 300122.SZ, 603392.SH, 300142.SZ and so on. In the medium and long term, with the increase in the penetration rate of HPV vaccines and the approval of more domestic vaccines, it will change from a supply-driven market to a demand-driven market. Product upgrading and overseas market development will become new highlights. It is recommended to pay attention to products.
Ruike Bio-B (02179.HK): leading Vaccine New Adjuvant Vaccine Pipeline layout is heavy
Shandong Boan Biotechnology Files for Hong Kong IPO
04:21 AM EDT, 05/16/2022 (MT Newswires) -- Shandong Boan Biotechnology filed its initial public offering application in Hong Kong and hired UBS Securities and Essence Corporate Finance as joint sponso
No Stock Yet